All In Biotech

Drug Trial Radar · NCT04919226

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin

Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 259 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

259

Actual

Start

Dec 21, 2021

Primary completion

Jun 2027

Study completion Sep 2027

Sponsor

Lead sponsor
ITM Solucin GmbHIndustry
Sponsor type
Industry
First posted
Jun 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.

Conditions

  • Neuroendocrine Tumors

Interventions

  • 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRTDrug

    Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-edotreotide with a defined number of cycles will be administered.

  • CAPTEM (Capecitabine and Temozolomide)Drug

    Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.

  • Amino-Acid SolutionOther

    The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.

  • EverolimusDrug

    Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.

  • FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)Drug

    Best standard of care treatment (investigator's choice \[from the protocol comparator list\]) according to individual risk-benefit assessment, institutional protocols, the local Prescribing Information, local regulations, or the local guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free SurvivalTime frame: Every 12 weeks from randomization until disease progression or death whichever occurs earlier, during the time necessary to observe 148 Progression Free Survival (PFS) events.

Locations

42 sites in 10 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Center

    Palo Alto, California

  • University of Colorado Hospital, Nuclear Medicine

    Aurora, Colorado

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic - Rochester, Department of Oncology

    Rochester, Minnesota

  • Washington University Alvin J. Siteman Cancer Center

    St Louis, Missouri

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • ICAHN School of Medicine at Mount Sinai, Tish Cancer Institute

    New York, New York

  • Duke University School of Medicine, Duke Cancer Institute

    Durham, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Texas Oncology

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Utah, Huntsman Cancer Institute

    Salt Lake City, Utah

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, China

  • Edouard Herriot Hospital, Medical Oncology Unit

    Lyon, France

  • IUCT Oncopole - Institut Universitaire du Cancer de Toulouse

    Toulouse, France

  • Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology

    Pessac, Bordeaux, France

  • Nantes University Hospital Center - Hotel Dieu Hospital

    Nantes, Cedex, France

  • Charite - University Hospital Berlin

    Berlin, Germany

  • University Hospital Bonn, Department of Nuclear Medicine

    Bonn, Germany

  • University Hospital Erlangen, Department of Internal Medicine I - Endocrinology

    Erlangen, Germany

  • University Duisburg-Essen, University Hospital Essen, Clinic for Nuclear Medicine

    Essen, Germany

  • Tata Memorial Hospital, Nuclear Medicine & Molecular Imaging

    Mumbai, India

  • HCG Cancer Centre, Medical Oncology

    Bangalore, Karnataka, India

  • All India Institute Of Medical Sciences, Nuclear Medicine

    New Delhi, National Capital Territory of Delhi, India

  • University Polyclinic Hospital "G. Martino", Department of Biomedical Sciences, Dentistry and Morphological and Functional Imaging, Complex Operational Unit of Nuclear Medicine

    Messina, Italy

  • European Institute of Oncology (IEO), IRCCS

    Milan, Italy

  • University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Complex Operative Unit of Medical Oncology

    Rome, Italy

  • VU Medical Center (VUMC), Department of Medical Oncology

    Amsterdam, Netherlands

  • Erasmus University Medical Center Rotterdam

    Rotterdam, Netherlands

  • University Hospital Vall d'Hebron, Department of Medical Oncology

    Barcelona, Spain

  • ICO Hospitalet, Catalan Institute of Oncology

    Barcelona, Spain

  • University General Hospital Gregorio Maranon

    Madrid, Spain

  • University Hospital 12 de Octubre, Department of Gastroenterology

    Madrid, Spain

  • Central University Hospital de Asturias (HUCA), IUOPA - Universitary Institute of Oncology

    Oviedo, Spain

  • University Hospital Complex of Santiago (CHUS)

    Santiago de Compostela, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.